Ying Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ying Cui has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Chao Ge
3 shared publications- Fangyu Zhao
State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
3 shared publications - Guo-Ping Jiang
Nanjing University of Posts and Telecommunications
3 shared publications - Haiyang Xie
Division of Hepatobiliary and Pancreatic Surgery Department of Surgery The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
3 shared publications - Hefen Sun
Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, China
3 shared publications - Hong Li
State Key Laboratory of Systems Medicine for Cancer Shanghai Cancer Institute Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
3 shared publications
Latest Publications
- 11 August 2026
- Published by Taylor & Francis in Current Eye Research
- p. 1-13
SGLT2i Canagliflozin Exerts Neuroprotection in Diabetic Retinopathy by Inhibiting Microglial Proinflammatory Cytokine Release by Downregulating the TLR4/NF-κB/NLRP3 Pathway
Diabetic retinopathy (DR) is the leading cause of preventable vision impairment among working-age adults.1 Its pathogenesis is multifactorial, characterized by retinal neurodegeneration and microva...
- 11 August 2026
- Published by Taylor & Francis in Current Eye Research
- p. 1-13
SGLT2i Canagliflozin Exerts Neuroprotection in Diabetic Retinopathy by Inhibiting Microglial Proinflammatory Cytokine Release by Downregulating the TLR4/NF-κB/NLRP3 Pathway
Diabetic retinopathy (DR) is the leading cause of preventable vision impairment among working-age adults.1 Its pathogenesis is multifactorial, characterized by retinal neurodegeneration and microva...
- Open Access
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Association of methionine-cycle dysregulation and reduced betaine with proliferative diabetic retinopathy and retinal microvascular alterations
Proliferative diabetic retinopathy (PDR) is the most vision-threatening stage of diabetic retinopathy (DR), a condition increasingly recognized as a neurovascular disorder in which dysregulation of the methionine cycle may impair the retinal neurovascular unit. In this retrospective observational study, targeted metabolomic profiling of the aqueous humor (AH) was performed in 40 eyes from 34 participants categorized into four groups: non-diabetic control individuals; (2) patients without DR; (3) patients with non-proliferative diabetic retinopathy (NPDR); and (4) patients with PDR. Eyes with PDR exhibited markedly elevated homocysteine (fold change 2.31, p < 0.05 vs. controls, with age and diabetes duration acknowledged as potential confounders, given the younger age and longer disease duration in the PDR group) and significantly reduced betaine (fold change 0.61, p < 0.05 vs. NPDR) levels, indicating disruption of the methionine cycle at the neovascular stage. To establish the biological relevance of these findings in AH, in vitro experiments in high-glucose-stimulated human retinal microvascular endothelial cells were performed, which demonstrated that betaine (1,000 μM) significantly suppressed endothelial proliferation, migration, and tube formation (p < 0.01 for proliferation and migration; p < 0.05 for tube formation) compared with high-glucose controls—providing a mechanistic link between the observed aqueous betaine depletion and pathological retinal angiogenesis. In an exploratory subset evaluated with widefield swept-source optical coherence tomography angiography (WF SS-OCTA; 12 eyes from 9 patients), betaine levels were found to be positively correlated with deep vascular complex density (r = 0.734, p = 0.007) and fractal dimension (r = 0.657, p = 0.020), while homocysteine was found to be negatively correlated with superficial vascular parameters (r = −0.623, p = 0.030), suggesting that methionine-cycle imbalance may reflect a broader neurovascular dysfunction. These findings position betaine as a candidate metabolic indicator warranting further investigation in PDR.
- 1 January 2026
- Published by Maximum Academic Press in Visual Neuroscience
- Vol. 43 (1)
Open AccessAssociation of methionine-cycle dysregulation and reduced betaine with proliferative diabetic retinopathy and retinal microvascular alterations
Proliferative diabetic retinopathy (PDR) is the most vision-threatening stage of diabetic retinopathy (DR), a condition increasingly recognized as a neurovascular disorder in which dysregulation of the methionine cycle may impair the retinal neurovascular unit. In this retrospective observational study, targeted metabolomic profiling of the aqueous humor (AH) was performed in 40 eyes from 34 participants categorized into four groups: non-diabetic control individuals; (2) patients without DR; (3) patients with non-proliferative diabetic retinopathy (NPDR); and (4) patients with PDR. Eyes with PDR exhibited markedly elevated homocysteine (fold change 2.31, p < 0.05 vs. controls, with age and diabetes duration acknowledged as potential confounders, given the younger age and longer disease duration in the PDR group) and significantly reduced betaine (fold change 0.61, p < 0.05 vs. NPDR) levels, indicating disruption of the methionine cycle at the neovascular stage. To establish the biological relevance of these findings in AH, in vitro experiments in high-glucose-stimulated human retinal microvascular endothelial cells were performed, which demonstrated that betaine (1,000 μM) significantly suppressed endothelial proliferation, migration, and tube formation (p < 0.01 for proliferation and migration; p < 0.05 for tube formation) compared with high-glucose controls—providing a mechanistic link between the observed aqueous betaine depletion and pathological retinal angiogenesis. In an exploratory subset evaluated with widefield swept-source optical coherence tomography angiography (WF SS-OCTA; 12 eyes from 9 patients), betaine levels were found to be positively correlated with deep vascular complex density (r = 0.734, p = 0.007) and fractal dimension (r = 0.657, p = 0.020), while homocysteine was found to be negatively correlated with superficial vascular parameters (r = −0.623, p = 0.030), suggesting that methionine-cycle imbalance may reflect a broader neurovascular dysfunction. These findings position betaine as a candidate metabolic indicator warranting further investigation in PDR.
- 23 October 2024
- Published by Springer Nature in Eye
- Vol. 39 (S1) , 88-89
Neurofibroma misdiagnosed as a chalazion
- 23 October 2024
- Published by Springer Nature in Eye
- Vol. 39 (S1) , 88-89
Neurofibroma misdiagnosed as a chalazion
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
CD133+ cancer stem cells (CSC) contribute to hepatocellular carcinoma (HCC) progression and resistance to therapy. Bone morphogenetic protein BMP4 plays an important role in hepatogenesis and hepatic stem cell differentiation, but little is known about its function in hepatic CSCs. In this study, we showed that high-dose exogenous BMP4 promotes CD133+ HCC CSC differentiation and inhibits the self-renewal, chemotherapeutic resistance, and tumorigenic capacity of these cells. Interestingly, we found that low-dose exogenous BMP4 upregulated CD133 protein expression in vitro, and endogenous BMP4 was preferentially expressed in CD133+ HCC CSCs, suggesting that low doses of BMP4 may facilitate CSC maintenance. A reduction in endogenous BMP4 levels decreased CD133 protein expression in vitro. In HCC tissues, expression of the BMP4 signaling target gene SMAD6 was positively correlated with CD133 expression. Activation of the Erk1/2 signaling pathway led to BMP4-mediated reduction in CD133 expression, which was reversed by treatment with MEK inhibitors. Taken together, our findings indicated that BMP4 might be a potent therapeutic agent in HCC that targets CSCs. Cancer Res; 72(16); 4276–85. ©2012 AACR.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
CD133+ cancer stem cells (CSC) contribute to hepatocellular carcinoma (HCC) progression and resistance to therapy. Bone morphogenetic protein BMP4 plays an important role in hepatogenesis and hepatic stem cell differentiation, but little is known about its function in hepatic CSCs. In this study, we showed that high-dose exogenous BMP4 promotes CD133+ HCC CSC differentiation and inhibits the self-renewal, chemotherapeutic resistance, and tumorigenic capacity of these cells. Interestingly, we found that low-dose exogenous BMP4 upregulated CD133 protein expression in vitro, and endogenous BMP4 was preferentially expressed in CD133+ HCC CSCs, suggesting that low doses of BMP4 may facilitate CSC maintenance. A reduction in endogenous BMP4 levels decreased CD133 protein expression in vitro. In HCC tissues, expression of the BMP4 signaling target gene SMAD6 was positively correlated with CD133 expression. Activation of the Erk1/2 signaling pathway led to BMP4-mediated reduction in CD133 expression, which was reversed by treatment with MEK inhibitors. Taken together, our findings indicated that BMP4 might be a potent therapeutic agent in HCC that targets CSCs. Cancer Res; 72(16); 4276–85. ©2012 AACR.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
PDF file - 639K, Supplementary Figure 1. CD133 is CSCs surface marker in PLC/PRF/5 cell line. Supplementary Figure 2. BMP4 showed pro-differentiation effect on HCC cell lines. Supplementary Figure 3. Tumorigenicity of CD133+/- HCC cells co-injected with BMP4 or vehicle embedding beads. Supplementary Figure 4. Canonical BMP4 signaling pathway switches on after exogenous BMP4 treatment. Supplementary Figure 5. BMP4 and SMAD6 expression in HCC cell lines. Supplementary Figure 6. Differentiated CSCs displayed enhanced Erk1/2 phosphorylation.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
PDF file - 639K, Supplementary Figure 1. CD133 is CSCs surface marker in PLC/PRF/5 cell line. Supplementary Figure 2. BMP4 showed pro-differentiation effect on HCC cell lines. Supplementary Figure 3. Tumorigenicity of CD133+/- HCC cells co-injected with BMP4 or vehicle embedding beads. Supplementary Figure 4. Canonical BMP4 signaling pathway switches on after exogenous BMP4 treatment. Supplementary Figure 5. BMP4 and SMAD6 expression in HCC cell lines. Supplementary Figure 6. Differentiated CSCs displayed enhanced Erk1/2 phosphorylation.
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
PDF file - 639K, Supplementary Figure 1. CD133 is CSCs surface marker in PLC/PRF/5 cell line. Supplementary Figure 2. BMP4 showed pro-differentiation effect on HCC cell lines. Supplementary Figure 3. Tumorigenicity of CD133+/- HCC cells co-injected with BMP4 or vehicle embedding beads. Supplementary Figure 4. Canonical BMP4 signaling pathway switches on after exogenous BMP4 treatment. Supplementary Figure 5. BMP4 and SMAD6 expression in HCC cell lines. Supplementary Figure 6. Differentiated CSCs displayed enhanced Erk1/2 phosphorylation.
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma
PDF file - 639K, Supplementary Figure 1. CD133 is CSCs surface marker in PLC/PRF/5 cell line. Supplementary Figure 2. BMP4 showed pro-differentiation effect on HCC cell lines. Supplementary Figure 3. Tumorigenicity of CD133+/- HCC cells co-injected with BMP4 or vehicle embedding beads. Supplementary Figure 4. Canonical BMP4 signaling pathway switches on after exogenous BMP4 treatment. Supplementary Figure 5. BMP4 and SMAD6 expression in HCC cell lines. Supplementary Figure 6. Differentiated CSCs displayed enhanced Erk1/2 phosphorylation.